These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35941631)

  • 21. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
    Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
    Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
    Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brand-Specific Enhanced Safety Surveillance Study of GSK's Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season.
    Dos Santos G; Wang H; Jindal P; Rybo M; Roul H; Pallem S; Eckermann T; Godderis L; Martínez Gómez X; Godard E; Soler M; Yousefi M; Salamanca de la Cueva I; Nwoji U
    Infect Dis Ther; 2022 Feb; 11(1):463-483. PubMed ID: 34961900
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season.
    Chabanon AL; Bricout H; Ballandras C; Souverain A; Caroe TD; Butler KM
    Hum Vaccin Immunother; 2018 Feb; 14(2):378-385. PubMed ID: 29148911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
    Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinón-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I;
    Vaccine; 2019 Mar; 37(13):1876-1884. PubMed ID: 30558818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season.
    Amicizia D; Domnich A; Lai PL; Orsi A; Icardi G; Tkach-Motulyak O; Panatto D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2190279. PubMed ID: 36919537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.
    Squarcione S; Sgricia S; Biasio LR; Perinetti E
    Vaccine; 2003 Mar; 21(11-12):1268-74. PubMed ID: 12559808
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.
    Pepin S; Szymanski H; Rochín Kobashi IA; Villagomez Martinez S; González Zamora JF; Brzostek J; Huang LM; Chiu CH; Chen PY; Ahonen A; Forstén A; Seppä I; Quiroz RF; Korhonen T; Rivas E; Monfredo C; Hutagalung Y; Menezes J; Vesikari T
    Hum Vaccin Immunother; 2016 Dec; 12(12):3072-3078. PubMed ID: 27565435
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: protocol of a pilot study in England.
    de Lusignan S; Dos Santos G; Correa A; Haguinet F; Yonova I; Lair F; Byford R; Ferreira F; Stuttard K; Chan T
    BMJ Open; 2017 May; 7(5):e015469. PubMed ID: 28515198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Safety Surveillance of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany, and Spain During the 2022/2023 Influenza Season.
    de la Cueva IS; Gerber JE; Hastie A; Brotons C; Panzer F; Pirçon JY; Talsma P; Eckermann T; Nikic V; Gomez XM; Alsdurf H
    Drug Saf; 2024 Jun; ():. PubMed ID: 38949714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India.
    Agarkhedkar S; Chhatwal J; Kompithra RZ; Lalwani SK; Narayan A; Muninarayanaswam V; Gogtay N; Dotter K; Gresset-Bourgeois V
    Hum Vaccin Immunother; 2019; 15(4):973-977. PubMed ID: 30762467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Active SMS-based influenza vaccine safety surveillance in Australian children.
    Pillsbury A; Quinn H; Cashman P; Leeb A; Macartney K;
    Vaccine; 2017 Dec; 35(51):7101-7106. PubMed ID: 29128379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.
    Montalban C; Montellano MB; Santos J; Lavis N
    Hum Vaccin Immunother; 2018 Mar; 14(3):593-595. PubMed ID: 28933626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial.
    Huang X; Fan T; Li L; Nian X; Zhang J; Gao X; Zhao W; Chen W; Zhang Z; Yao Z; Han X; Shi J; Wang Y; Bian H; Shi N; Li X; Duan K; Li G; Yang X
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079924. PubMed ID: 35714276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
    Folschweiller N; Vanden Abeele C; Chu L; Van Damme P; García-Sastre A; Krammer F; Nachbagauer R; Palese P; Solórzano A; Bi D; David MP; Friel D; Innis BL; Koch J; Mallett CP; Rouxel RN; Salaun B; Vantomme V; Verheust C; Struyf F
    Lancet Infect Dis; 2022 Jul; 22(7):1062-1075. PubMed ID: 35461522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial.
    Shinde V; Cho I; Plested JS; Agrawal S; Fiske J; Cai R; Zhou H; Pham X; Zhu M; Cloney-Clark S; Wang N; Zhou B; Lewis M; Price-Abbott P; Patel N; Massare MJ; Smith G; Keech C; Fries L; Glenn GM
    Lancet Infect Dis; 2022 Jan; 22(1):73-84. PubMed ID: 34563277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quadrivalent inactivated influenza vaccine (VaxigripTetra™).
    Gresset-Bourgeois V; Leventhal PS; Pepin S; Hollingsworth R; Kazek-Duret MP; De Bruijn I; Samson SI
    Expert Rev Vaccines; 2018 Jan; 17(1):1-11. PubMed ID: 29157068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
    Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
    Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.
    Chu K; Xu K; Tang R; Tian X; Hu J; Yang T; Li C; Hu Y; Zeng G
    Vaccine; 2020 Aug; 38(37):5940-5946. PubMed ID: 32732142
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.